Stockreport

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program [Yahoo! Finance]

Inhibrx, Inc.  (INBX) 
PDF company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda ® (pembrolizumab [Read more]